Form 4 Tracker
TEVA PHARMACEUTICAL INDUSTRIES LTD
TEVA

64 insider filings · Latest: Jun 18, 2026

Common Stock Transactions
Txn DateAcceptedInsiderTypeSharesAvg PriceValueShares OwnedFiling
Mar 17, 2026Mar 17 8:15 PMSabag Mark
Proposed Sale
62,102$30.14$1.9M

View →

Mar 5, 2026Mar 9 8:18 PMRichard D FrancisPresident and CEO
Sale
20,025$31.67$634.2K1,170,639(D)

View →

Mar 5, 2026Mar 9 8:16 PMChristine FoxEVP, U.S. Commercial
Sale
7,924$31.67$250.9K84,905(D)

View →

Mar 5, 2026Mar 9 8:14 PMEric A HughesSee "Remarks"
Sale
9,533$31.67$301.9K107,711(D)

View →

Mar 5, 2026Mar 9 8:12 PMRichard DaniellEVP, Europe Commercial
Sale
17,295$31.67$547.7K85,755(D)

View →

Mar 5, 2026Mar 9 8:10 PMPlacid JoverSee "Remarks"
Sale
14,150$31.67$448.1K6,774(D)

View →

Mar 5, 2026Mar 9 8:09 PMBrian SavageInterim Chief Legal Officer
Sale
1,127$31.67$35.7K10,914(D)

View →

Mar 5, 2026Mar 9 8:05 PMMatthew ShieldsEVP, Global Operations
Sale
17,295$31.67$547.7K9,989(D)

View →

Mar 4, 2026Mar 6 9:19 PMRichard D FrancisPresident and CEO
Sale
23,393$32.46$759.4K1,148,212(D)

View →

Mar 4, 2026Mar 6 9:17 PMRichard DaniellEVP, Europe Commercial
Sale
91,345$32.66$3.0M85,755(D)

View →

Mar 4, 2026Mar 6 9:09 PMEric A HughesSee "Remarks"
Sale
11,277$32.46$366.1K97,590(D)

View →

Mar 4, 2026Mar 6 9:05 PMChristine FoxEVP, U.S. Commercial
Sale
9,098$32.46$295.4K75,010(D)

View →

Mar 4, 2026Mar 6 9:03 PMBrian SavageInterim Chief Legal Officer
Sale
2,675$32.46$86.8K8,461(D)

View →

Mar 5, 2026Mar 5 10:49 PMShields Matthew
Proposed Sale
17,295$31.67$547.7K

View →

Mar 5, 2026Mar 5 10:43 PMJover Placid
Proposed Sale
14,150$31.67$448.1K

View →

Mar 5, 2026Mar 5 10:39 PMSavage Brian
Proposed Sale
1,127$31.67$35.7K

View →

Mar 5, 2026Mar 5 10:32 PMFox Christine
Proposed Sale
7,924$31.67$250.9K

View →

Mar 5, 2026Mar 5 10:26 PMFrancis Richard D
Proposed Sale
20,025$31.67$634.2K

View →

Mar 5, 2026Mar 5 10:13 PMHughes Eric A
Proposed Sale
9,533$31.67$301.9K

View →

Mar 5, 2026Mar 5 10:08 PMDaniell Richard
Proposed Sale
17,295$31.67$547.7K

View →

Stock Options & Derivatives
Txn DateAcceptedInsiderTypeSharesExercise PriceShares OwnedFiling
Jan 27, 2026Jan 29 9:04 PMMark SabagSee "Remarks"
Grant/Award
141,478141,478(D)

View →

Jan 27, 2026Jan 29 9:02 PMRichard DaniellExec. VP, European Commercial
Grant/Award
141,478141,478(D)

View →

Jan 27, 2026Jan 29 9:01 PMRichard D FrancisPresident and CEO
Grant/Award
1,511,425891,315(D)

View →

← Previous

Page 4 of 4